Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx-99 an Experimental Treatment for COVID-19
Excerpt from the Press Release:
MENLO PARK, Calif.–(BUSINESS WIRE)–Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it has been granted approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to conduct a Phase 1 clinical study of REVTx-99 in healthy volunteers (RVL-HV01 study). HREC approval permitted Revelation to complete the required Clinical Trial Notification to the Therapeutic Goods Administration. REVTx-99 is in development as an early treatment for SARS-CoV-2 Infection (COVID-19). RVL-HV01 is a single site, placebo-controlled, single dose, escalating dose study to determine the safety and tolerability of intranasal REVTx-99 in healthy adult volunteers. The study is expected to begin enrolling participants in Q4 2020.
“We are excited to announce the initiation of clinical development for REVTx-99, our first pipeline candidate to enter Phase 1 clinical study,” said James Rolke, Chief Executive Officer of Revelation. “Due to the severity and high hospitalization rate of SARS-CoV-2 infection and the urgent need for effective treatments, we are looking forward to embarking on clinical development and rapidly advancing this therapeutic candidate.”
Click the button below to continue reading the Press Release:
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?